Annual Accounts Receivable
$19.66 M
+$2.38 M+13.77%
31 December 2023
Summary:
Standard BioTools annual accounts receivable is currently $19.66 million, with the most recent change of +$2.38 million (+13.77%) on 31 December 2023. During the last 3 years, it has fallen by -$5.76 million (-22.67%). LAB annual accounts receivable is now -22.77% below its all-time high of $25.46 million, reached on 01 December 2015.LAB Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$35.34 M
+$7.23 M+25.74%
30 September 2024
Summary:
Standard BioTools quarterly accounts receivable is currently $35.34 million, with the most recent change of +$7.23 million (+25.74%) on 30 September 2024. Over the past year, it has increased by +$18.78 million (+113.39%). LAB quarterly accounts receivable is now -1.87% below its all-time high of $36.01 million, reached on 31 March 2024.LAB Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LAB Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +13.8% | +113.4% |
| 3 y3 years | -22.7% | +157.3% |
| 5 y5 years | +18.1% | +86.2% |
LAB Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -22.7% | +13.8% | -1.9% | +223.1% |
| 5 y | 5 years | -22.7% | +18.1% | -1.9% | +254.0% |
| alltime | all time | -22.8% | +1013.9% | -1.9% | +1759.8% |
Standard BioTools Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $35.34 M(+25.7%) |
| June 2024 | - | $28.10 M(-22.0%) |
| Mar 2024 | - | $36.01 M(+83.2%) |
| Dec 2023 | $19.66 M(+13.8%) | $19.66 M(+18.7%) |
| Sept 2023 | - | $16.56 M(+9.5%) |
| June 2023 | - | $15.12 M(+4.2%) |
| Mar 2023 | - | $14.50 M(-16.1%) |
| Dec 2022 | $17.28 M(-5.7%) | $17.28 M(-0.1%) |
| Sept 2022 | - | $17.29 M(+58.1%) |
| June 2022 | - | $10.94 M(-29.1%) |
| Mar 2022 | - | $15.42 M(-15.8%) |
| Dec 2021 | $18.32 M(-27.9%) | $18.32 M(+33.4%) |
| Sept 2021 | - | $13.73 M(-12.3%) |
| June 2021 | - | $15.67 M(+1.6%) |
| Mar 2021 | - | $15.41 M(-39.4%) |
| Dec 2020 | $25.42 M(+33.9%) | - |
| Dec 2020 | - | $25.42 M(+44.3%) |
| Sept 2020 | - | $17.61 M(+76.4%) |
| June 2020 | - | $9.98 M(-30.7%) |
| Mar 2020 | - | $14.41 M(-24.1%) |
| Dec 2019 | $18.98 M(+14.0%) | - |
| Dec 2019 | - | $18.98 M(+35.4%) |
| Sept 2019 | - | $14.01 M(-27.2%) |
| June 2019 | - | $19.26 M(-0.2%) |
| Mar 2019 | - | $19.31 M(+16.0%) |
| Dec 2018 | $16.65 M(+10.6%) | $16.65 M(-9.4%) |
| Sept 2018 | - | $18.38 M(+8.9%) |
| June 2018 | - | $16.87 M(+3.7%) |
| Mar 2018 | - | $16.27 M(+8.1%) |
| Dec 2017 | $15.05 M | $15.05 M(+9.6%) |
| Sept 2017 | - | $13.73 M(+0.5%) |
| June 2017 | - | $13.66 M(-5.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2017 | - | $14.39 M(-1.5%) |
| Dec 2016 | $14.61 M(-42.6%) | $14.61 M(+13.8%) |
| Sept 2016 | - | $12.84 M(-32.0%) |
| June 2016 | - | $18.89 M(-3.9%) |
| Mar 2016 | - | $19.64 M(-22.8%) |
| Dec 2015 | $25.46 M(+13.7%) | $25.46 M(-3.0%) |
| Sept 2015 | - | $26.25 M(+20.5%) |
| June 2015 | - | $21.79 M(+11.3%) |
| Mar 2015 | - | $19.58 M(-12.5%) |
| Dec 2014 | $22.38 M(+112.1%) | $22.38 M(+32.3%) |
| Sept 2014 | - | $16.92 M(+26.9%) |
| June 2014 | - | $13.33 M(-29.1%) |
| Mar 2014 | - | $18.79 M(+78.1%) |
| Dec 2013 | $10.55 M(-18.2%) | $10.55 M(-15.0%) |
| Sept 2013 | - | $12.41 M(+14.5%) |
| June 2013 | - | $10.84 M(+7.8%) |
| Mar 2013 | - | $10.06 M(-22.0%) |
| Dec 2012 | $12.90 M(+39.4%) | $12.90 M(+21.1%) |
| Sept 2012 | - | $10.65 M(+10.8%) |
| June 2012 | - | $9.61 M(-1.6%) |
| Mar 2012 | - | $9.76 M(+5.5%) |
| Dec 2011 | $9.25 M(+14.2%) | $9.25 M(+3.2%) |
| Sept 2011 | - | $8.97 M(-13.1%) |
| June 2011 | - | $10.32 M(+38.3%) |
| Mar 2011 | - | $7.46 M(-7.9%) |
| Dec 2010 | $8.10 M(-6.8%) | $8.10 M(+17.6%) |
| Sept 2010 | - | $6.89 M(-20.8%) |
| Dec 2009 | $8.69 M(+84.7%) | $8.69 M(+84.7%) |
| Dec 2008 | $4.71 M(+147.7%) | $4.71 M(+88.6%) |
| June 2008 | - | $2.50 M(+31.3%) |
| Dec 2007 | $1.90 M(+7.6%) | $1.90 M |
| Dec 2006 | $1.76 M | - |
FAQ
- What is Standard BioTools annual accounts receivable?
- What is the all time high annual accounts receivable for Standard BioTools?
- What is Standard BioTools annual accounts receivable year-on-year change?
- What is Standard BioTools quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Standard BioTools?
- What is Standard BioTools quarterly accounts receivable year-on-year change?
What is Standard BioTools annual accounts receivable?
The current annual accounts receivable of LAB is $19.66 M
What is the all time high annual accounts receivable for Standard BioTools?
Standard BioTools all-time high annual accounts receivable is $25.46 M
What is Standard BioTools annual accounts receivable year-on-year change?
Over the past year, LAB annual accounts receivable has changed by +$2.38 M (+13.77%)
What is Standard BioTools quarterly accounts receivable?
The current quarterly accounts receivable of LAB is $35.34 M
What is the all time high quarterly accounts receivable for Standard BioTools?
Standard BioTools all-time high quarterly accounts receivable is $36.01 M
What is Standard BioTools quarterly accounts receivable year-on-year change?
Over the past year, LAB quarterly accounts receivable has changed by +$18.78 M (+113.39%)